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Introduction
Targeted radiation therapy for breast cancer is a rational approach, however; there are problems associated with low receptor expression on tumors and bone marrow toxicity due to the long serum half-life of antibodies used to target the radiation. A novel method to overcome these problems was investigated. An adenoviral vector encoding the human somatostatin receptor subtype 2 (AdSSTr2) was produced. The MDA-MB-468 and BT-474 human breast cancer cells were infected with AdSSTr2 and harvested 48 h later for membrane preparations.
Membrane SSTr2 expression will be determined by a competitive binding assay using iodine-125 (I-125)-labeled somatostatin. Localization of technetium-99m (Tc-99m)-P2045 (a high affinity somatostatin analogue) in mice bearing subcutaneous MDA-MB-468 tumors was evaluated by injecting AdSSTr2 i.v. followed by an i.v. injection of Tc-99m-P2045 48 h later.
Localization of Tc-99m-P2045 was determined by counting tissues in a gamma counter.
Therapy studies were to be conducted using AdSSTr2 followed by therapeutic doses of i.v. administered Y-90-SMT 487, however, time did not allow the completion of these studies.
Overall, these studies provided the proof-of-principle that this novel paradigm can be used to treat and detect breast cancer. Construction of AdCMVhSSTr2. A recombinant adenovirus encoding the human somatostatin receptor subtype 2 cDNA was prepared using standard techniques described by Graham and Prevec (1) . This is similar to the method described previously for the construction of the adenovirus encoding the murine gastrin releasing peptide receptor (2) . Briefly, a cDNA Competitive Binding Analyses. The induction of SSTr2 in human breast cancer cell lines was evaluated using a radiolabeled peptide binding assay to cell membrane preparations of cells that had been infected with AdSSTr2. The cells were seeded such that they were -80% confluent at the time they were infected with AdSSTr2 and then harvested for membrane preparations 2 days after adenoviral infection. The AdSSTr2 (50 pfu per cell) was added to cells in Optimem© (Gibco-BRL, Grand Island, NY) and incubated at 37°C in 5% C0 2 for 2 h. The cells were then supplemented with complete media and incubated an additional 48 h at 37°C.
Body
Cell membranes were then prepared from the infected and uninfected cells using a protocol similar to that previously described (3) (4) (5) (6) . Briefly, the cells were washed with phosphate buffered saline, scraped from the flask, and centrifuged at 90 x g for 5 min at 4°C. The pellet was resuspended in cold lysis buffer (10 raM Tris-HCl, 2 mM EDTA, 2 mM MgCl 2 , pH 7.2) containing 0.5 mM phenylmethylsulfonyl fluoride and incubated on ice for 15 min. The mixture was vortexed, centrifuged at 600 x g for 15 min at 4°C, and the supernatant removed and stored on ice. An additional lysis step was performed on the pellet and the two supernatants were combined. The supernatant was centrifuged at 28,000 x g for 30 min at 4°C, the resulting supernatant discarded, and the pellet resuspended in 250 mM sucrose, 20 mM glycylglycine, and 1 mM MgCl 2 . A BioRad (Hercules, CA) protein assay was performed to determine the protein concentration and the samples aliquoted and stored at -80°C.
For the binding assays, the membrane preparations were thawed and diluted in buffer (10 mM HEPES, 5 mM MgCl 2 , 1 mM EDTA and 0.1% bovine serum albumin, 10 ug/ml leupeptin, 10 jig/ml pepstatin, 0.5 ug/ml aprotinin, and 200 ug/ml bacitracin, pH 7.4) to 25 u,g per sample.
Individual samples were added to Multiscreen Durapore filtration plates (type FB, 1.0 um borosilicate glass fiber over 1. AdSSTr2. This represents a > 50-fold increase in the uptake of 99m Tc-P2045 in the liver. Other tissue showed a 2-5-fold increase in 99m Tc-P2045 uptake after injection of AdSSTr2 when compared to controls. These studies demonstrate that AdSSTr2 can infect MDA-MB-468 cells after i.v. injection, which can accumulate 99m Tc-P2045.
Key Research Accomplishments
Demonstration that AdSSTr2 could be used to induce expression of SSTr2 on BT-474
and MDA-MB-468 human breast cancer cells.
The expression of SSTr2 was greater on MDA-MB-468 cells than on BT-474 cells after AdSSTr2 expression.
AdSSTr2 could induce expression of SSTr2 on subcutaneous MDA-MB-468 tumors as
shown by uptake of 99m Tc-P2045.
Reportable Outcomes
None, these results have not been written-up for an abstract or manuscript. It is likely that more data will need to be collected prior to submission of a manuscript.
Conclusions
In conclusion, these studies show that AdSSTr2 can be used to express proof of principle data to be generated.
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